Company
Soligenix
Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Also known as Soligenix, Inc.
- Status
- IPOas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Soligenix, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Funding snapshot
- Total raised
- $13.9MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $2M2017-11-02
Funding rounds
- Round, 2017
- $2M2017-11-02, SEC form D sold, 6 investors
- Round, 2013
- $1.5M2013-04-27, SEC form D sold, 1 investor
- Round, 2010
- $5.9M2010-06-18, SEC form D sold, 46 investors
- Round, 2008
- $4.5M2008-12-01, SEC form D sold, 6 investors
About the company
- Status notes
- Soligenix, Inc. (Nasdaq: SNGX)
Products
- Other
- HyBryte
- Other
- RiVax
- Other
- SGX302
- Other
- SGX942
- Other
- SGX945
- Other
- ThermoVax
Loading relationship preview